Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -24.2%
- Operating Margin Trend +10753.29 pp/yr
KROS
Keros Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -27.5%
- 5yr Share-Count CAGR 12.9%
Growth Quality
Weight: 25%
C+
60
- 5yr Revenue CAGR 86.7%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
D+
43
- 5yr FCF Margin -22236.1%
- 5yr FCF/NI Conversion 1.22x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -2.90x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 6.06
Stability
Weight: 5%
A-
80
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed.
- Holders
- 2
- Avg Δ position
- +74.0%
- New buys
- 0
- Full exits
- 0